drugset / Trial / NCT00003458

Antineoplaston Therapy in Treating Children With Brain Tumors

NCT00003458

Phase 2 Completed 34 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Current therapies for childhood brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) with brain tumors.

Timeline

Start
1996-09
Primary completion
2014-09
Completion
2014-09

Publications

  • Background Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek. A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10). Journal of Cancer Therapy 8: 173-187, 2017

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications